CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis

• Main Authors: Xiaoli Li (Author), Xiaoping Yu (Author), Duanfang Zhou (Author), Bo Chen (Author), Wenjun Li (Author), Xiangru Zheng (Author), Hongfang Zeng (Author), Liangyuan Long (Author), Weiying Zhou (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Triple-negative breast cancer (TNBC) has a poor prognosis due to the lack of specific therapeutic targets. CCT020312, a selective eukaryotic translation initiation factor 2 alpha (eIF2α)/protein kinase RNA-like endoplasmic reticulum kinase (PERK) activator, may have a potent anti-tumor effect. In th...